New York, NY -- (SBWIRE) -- 01/21/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Synta Pharmaceuticals Corp (NASDAQ:SNTA), Opko Health Inc (NYSE:OPK), VIVUS, Inc (NASDAQ:VVUS), Acasti Pharma Inc (NASDAQ:ACST)
Synta Pharmaceuticals Corp (NASDAQ:SNTA) showed a volume of 1.81 million shares by the end of last trade whereas the average volume of the stock remained 1.89 million shares. The stock opened the session at $6.35 but then moved to $6.17. At that price, the stock showed a negative performance of -2.68%. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.
Will SNTA Get Buyers Even After The Recent Rally? Find Out Here
Opko Health Inc (NYSE:OPK) opened the session at $8.90 and closed the session at $8.72. The stock showed a negative performance of -0.91% in previous trading session. Traded with volume of 1.82 million shares in the prior session and the average volume of the stock remained 4.89 million shares. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests,
Has OPK Found The Bottom And Ready To Gain Momentum? Find Out Here
VIVUS, Inc (NASDAQ:VVUS) opened the session at $9.37 and closed the session at $9.16. The stock showed a negative performance of -0.22% in previous trading session. Traded with volume of 1.78 million shares in the prior session and the average volume of the stock remained 1.76 million shares. The beta of the stock remained 1.31. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug,
Why Should Investors Buy VVUS After the Recent Fall? Just Go Here and Find Out
Acasti Pharma Inc (NASDAQ:ACST) the stock advanced 0.71% and finished the session at $1.41. Traded with volume of 1.77 million shares in the prior session and the average volume of the stock remained 536,052.00 shares. Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.
Will ACST Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)